ARF6 and breast carcinoma: Since the GEP100-Arf6-AMAP1 pathway is common in pathologic angiogenesis and invasion/metastasis of many breast cancers, we propose that components of the GEP100-Arf6-AMAP1-cortactin pathway provide novel molecular targets for treatment of malignant cancers, as well as other diseases characterized by hyper-angiogenesis.